hERG potassium channels and cardiac arrhythmia

Nature

Volumn 440, Issue 7083, 2006, Pages 463-469

  Sanguinetti, Michael C ^a,b   Tristani Firouzi, Martin ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYSTAL STRUCTURE; DRUG THERAPY; GENES; MUTAGENS;

ARRHYTHMIA; DRUG FAILURE; POTASSIUM CHANNELS;

POTASSIUM;

1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; GREPAFLOXACIN; NEUROLEPTIC AGENT; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; QUINIDINE; SERTINDOLE; TERFENADINE;

POTASSIUM;

ACTION POTENTIAL; ALLERGY; CELL TYPE; CENTRAL NERVOUS SYSTEM; CHANNEL GATING; CRYSTAL STRUCTURE; ELECTRIC ACTIVITY; GASTROINTESTINAL DISEASE; GENE MUTATION; HEART ARRHYTHMIA; HEART DISEASE; HEART MUSCLE POTENTIAL; HUMAN; LONG QT SYNDROME; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QT INTERVAL; REPOLARIZATION; REVIEW; SAFETY; STRUCTURE ANALYSIS; WORLD HEALTH ORGANIZATION; X RAY CRYSTALLOGRAPHY;

EID: 33645317063     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature04710     Document Type: Review

References (88)

1. Warmke, J. W. & Ganetzky, B. A family of potassium channelgenes related to eag in Drosophila and mammals. Proc. Natl Acad. Sci USA 91, 3438-3442 (1994).
2. Curran, M. E. et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80, 795-803 (1995).
3. Haverkamp, W. et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur. Heart J. 21, 1216-1231 (2000).
4. + conduction and selectivity. Science 280, 69-77 (1998).
5. Jiang, Y. et al. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 417, 515-522 (2002).
6. + channel. Nature 423, 33-41 (2003).
7. + channel. Science 309, 897-903 (2005).
8. Farrelly, A. M. et al. Expression and function of KCNH2 (HERG) in the human jejunum. Am. J. Physiol. 284, G883-G895 (2003).
9. + channels: spike-frequency adaptation. J. Physiol. (Lond.) 501, 313-318 (1997).
10. + channels in neoplastic hematopoietic cells. J. Biol. Chem. 277, 18528-18534 (2002).
11. Shi, W. et al. Identification of two nervous system-specific members of the erg potassium channel gene family. J. Neurosci. 17, 9423-9432 (1997).
12. Wimmers, S., Wulfsen, I., Bauer, C. K. & Schwarz, J. R. Erg1, erg2 and erg3 K channel subunits are able to form heteromultimers. Pflugers Arch. 441, 450-455 (2001).
13. Kr potassium channel. Cell 81, 299-307 (1995).
14. Trudeau, M., Warmke, J. W., Ganetzky, B. & Robertson, G. A. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269, 92-95 (1995).
15. Bennett, P. B., Yazawa, K., Makita, N. & George, A. L. Molecular mechanism for an inherited cardiac arrhythmia. Nature 376, 683-685 (1995).
16. Plaster, N. M. et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 105, 511-519 (2001).
17. V1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19-31 (2004).
18. Furutani, M. et al. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation 99, 2290-2294 (1999).
19. Delisle, B. P., Anson, B. D., Rajamani, S. & January, C. T. Biology of cardiac arrhythmias: ion channel protein trafficking. Circ Res. 94, 1418-1428 (2004).
20. Gong, Q., Keeney, D. R., Molinari, M. & Zhou, Z. Degradation of trafficking-defective long QT syndrome type II mutant channels by the ubiquitin-proteasome pathway. J. Biol. Chem. 280, 19419-19425 (2005).
21. + channel dysfunction in an inherited cardiac arrhythmia. Proc. Natl Acad. Sci. USA 93, 2208-2212 (1996).
22. Kagan, A., Yu, Z., Fishman, G. I. & McDonald, T. V. The dominant negative LQT2 mutation A561V reduces wild-type HERG expression. J. Biol. Chem. 275, 11241-11248 (2000).
23. Nakajima, T. et al. Novel mechanism of HERG current suppression in LQT2: shift in voltage dependence of HERG inactivation. Circ. Res. 83, 415-422 (1998).
24. Brugada, R. et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109, 30-35 (2004).
25. + channel-Fab complex at 2.0 Å resolution. Nature 414, 43-48 (2001).
26. Jiang, Y., Lee, A., Cadene, M., Chait, B. T. & MacKinnon, R. The open pore conformation of potassium channels. Nature 417, 523-526 (2002).
27. Long, S. B., Campbell, E. B. & MacKinnon, R. Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science 309, 903-908 (2005).
28. Mitcheson, J. S., Chen, J., Lin, M., Culberson, C. & Sanguinetti, M. C. A structural basis for drug-induced long QT syndrome. Proc. Natl Acad. Sci. USA 97, 12329-12333 (2000).
29. + channels defined by high-affinity metal bridges. Nature 428, 864-868 (2004).
30. Fernandez, D., Ghanta, A., Kauffman, G. W. & Sanguinetti, M. C. Physicochemical features of the hERG channel drug binding site. J. Biol. Chem. 279, 10120-10127 (2004).
31. Morais Cabral, J. H. et al. Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell 95, 649-655 (1998).
32. Taylor, B. L. & Zhulin, I. B. PAS domains: internal sensors of oxygen, redox potential, and light. Microbiol. Mol. Biol. Rev. 63, 479-506 (1999).
33. + current. Circ. Res. 81, 870-878 (1997).
34. + channel by dual pathways. Curr. Biol. 10, 671-674 (2000).
35. Akhavan, A. et al. Identification of the cyclic-nucleotide-binding domain as a conserved determinant of ion-channel cell-surface localization. J. Cell Sci. 118, 2803-2812 (2005).
36. Ks cardiac potassium channel. Nature 384, 78-80 (1996).
37. Ks potassium channel. Nature 384, 80-83 (1996).
38. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97, 175-187 (1999).
39. Pourrier, M., Zicha, S., Ehrlich, J., Han, W. & Nattel, S. Canine ventricular KCNE2 expression resides predominantly in Purkinje fibers. Circ. Res. 93, 189-191 (2003).
40. Ks. J. Mol. Cell. Cardiol. 38, 277-287 (2005).
41. Weerapura, M., Nattel, S., Chartier, D., Caballero, R. & Hebert, T. E. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J. Physiol. (Lond.) 540, 15-27. (2002).
42. Sesti, F. et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl Acad. Sci. USA 97, 10613-10618 (2000).
43. Noble, D. & Tsien, R. W. Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibres. J. Physiol. (Lond) 200, 205-231 (1969).
44. Shibasaki, T. Conductance and kinetics of delayed rectifier potassium channels in nodal cells of the rabbit heart. J. Physiol. (Lond.) 387, 227-250 (1987).
45. Clay, J. R., Hill, C. E., Roitman, D. & Shrier, A. Repolarization current in embryonic chick atrial heart cells. J. Physiol. (Lond.) 403, 525-537 (1988).
46. + current: Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96, 195-215 (1990).
47. Piper, D. R., Varghese, A., Sanguinetti, M. C. & Tristani-Firouzi, M. Gating currents associated with intramembrane charge displacement in HERG potassium channels. Proc. Natl Acad. Sci. USA 100, 10534-10539 (2003).
48. Smith, P. L. & Yellen, G. Fast and slow voltage sensor movements in HERG potassium channels. J. Gen. Physiol. 119, 275-293 (2002).
49. + channel: The S4 domain is loosely packed and likely to be lipid exposed. J. Physiol. (Lond.) 569, 367-379 (2005).
50. Piper, D. R., Hinz, W. A., Tallurri, C. K., Sanguinetti, M. C. & Tristani-Firouzi, M. Regional specificity of human ether-a′-go-go-related gene channel activation and inactivation gating. J. Biol. Chem. 280, 7206-7217 (2005).
51. Zhang, M., Liu, J. & Tseng, G. N. Gating charges in the activation and inactivation processes of the HERG channel. J. Gen. Physiol. 124, 703-718 (2004).
52. + channel S4. Neuron 16, 387-397 (1996).
53. + channels. Proc. Natl Acad. Sci. USA 100, 2935-2940 (2003).
54. Liu, J., Zhang, M., Jiang, M. & Tseng, G. N. Negative charges in the transmembrane domains of the HERG K channel are involved in the activation- and deactivation-gating processes. J. Gen. Physiol. 121, 599-614 (2003).
55. 2+-induced modification of human ether-a-go-go-related gene (hERG) channel activation. J. Physiol. (Lond.) 567, 737-755 (2005).
56. Laine, M., Papazian, D. M. & Roux, B. Critical assessment of a proposed model of Shaker. FEBS Lett. 564, 257-263 (2004).
57. + channel voltage sensor measured with luminescence energy transfer. Nature 436, 848-851 (2005).
58. + channel. Nature 423, 42-48 (2003).
59. + channel. Cell 123, 463-475 (2005).
60. + channels. J. Gen. Physiol. 120, 663-676. (2002).
61. + channels. J. Biol. Chem. 277, 18994-19000 (2002).
62. Kr channel. J. Gen. Physiol. 107, 611-619 (1996).
63. Smith, P. L., Baukrowitz, T. & Yellen, G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379, 833-836 (1996).
64. Fan, J.-S., Jinag, M., Dun, W., McDonald, T. V. & Tseng, G.-N. Effects of outer mouth mutations on hERG channel function: A comparison with similar mutations in the Shaker channel. Biophys. J. 76, 3128-3140 (1999).
65. +]: A tale of two inactivation mechanisms. Neuron 15, 951-960 (1995).
66. + at the potassium channel selectivity filter. Biophys. J. 74, 1840-1849 (1998).
67. De Bruin, M. L., Pettersson, M., Meyboom, R. H., Hoes, A. W. & Leufkens, H. G. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 26, 590-597 (2005).
68. Vitola, J., Vukanovic, J. & Roden, D. M. Cisapride-induced torsades de pointes. J. Cardiovasc. Eledrophysiol. 9, 1109-1113 (1998).
69. + channel blockade: current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. 25, 133-166 (2005).
70. Kuryshev, Y. A. et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312, 316-323 (2005).
71. + channel blockers. J. Med. Chem. 45, 3844-3853 (2002).
72. Ekins, S., Crumb, W. J., Sarazan, R. D., Wikel, J. H. & Wrighton, S. A. Three-dimensional quantitative structure-activity relationship for inhibition of human eiher-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. 301, 427-434 (2002).
73. Pearlstein, R. A. et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. 13, 1829-1835 (2003).
74. Sanguinetti, M. C. & Mitcheson, J. S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 26, 119-124 (2005).
75. Dubin, A. E. et al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J. Biomol. Screen. 10, 168-181 (2005).
76. + channel. A model for bad behavior. J. Med. Chem. 46, 2017-2022 (2003).
77. + channel: application to ligand binding. Bioorg. Med. Chem. Lett. 15, 1737-1741 (2005).
78. + channel using docking and molecular dynamics methods. FEBS Lett 579, 2939-2944 (2005).
79. Lastraioli, E. et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res. 64, 606-611 (2004).
80. + channel. Mol. Pharmacol. 67, 827-836 (2005).
81. Wang, Q. et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nature Genetics 12, 17-23 (1996).
82. Ks function. Nature Genet. 17, 338-340 (1997).
83. Wang, Q. et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80, 805-811 (1995).
84. Chen, Q. et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392, 293-296 (1998).
85. Priori, S. G. et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103, 196-200 (2001).
86. Priebe, L. & Beuckelmann, D. J. Simulation study of cellular electric properties in heart failure. Circ. Res. 82, 1206-1223 (1998).
87. Priori, S. G. et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res. 96, 800-807 (2005).
88. Schott, J.-J. et al. Cardiac conduction defects associate with mutations in SCN5A. Nature Genet. 23, 20-21 (1999).